Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vyleesi (bremelanotide) in lactating women
NCT06867835Phase 4Completed
- Start
- Jul 2025
- Primary completion
- Nov 2025
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of bremelanotide. Primary endpoints: Levels of Bremelanotide in Breast Milk Over 24h After Administration of Vyleesi, Area Under the Curve from Time 0 to End of Dosing Interval for BMT in Breast Milk at 24 hours and 3 more. Started Jul 2025; status: completed.
02
Drugs
bremelanotide
Beyond the preview
Go deeper on NCT06867835.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06867835.